World News

Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer

https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c

Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer (MedPage Today) — SAN FRANCISCO — Adding modified FOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) and bevacizumab (Avastin) to atezolizumab (Tecentriq) significantly improved progression-free survival (PFS) in patients with previously untreated…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button